Indegene Ltd IPO: Issue Details, Open/Close Date | Research 360 by Motilal Oswal
Back arrow




-1.45 (-0.26%)

  • DRHP

Offer Price

₹ 1,841.76 Cr

Issue Size

₹ 14,916

Min Investment


Times Subscribed


Lot size

Time Line

  • 06
    May 2024
  • 08
    May 2024
  • 09
    May 2024
    Finalisation of Basis of Allotment
  • 10
    May 2024
    Initiation of Refunds
  • 10
    May 2024
    Transfer of Shares to Demat Account
  • 13
    May 2024
    Listing Date

Shares Offered

Number of Times Subscribed

Objects of the Offer

  • Strengthen its "go to market" engine.

  • Develop its technology portfolio.

  • Pursue strategic acquisitions.

  • Focus on operational excellence.

Products & Services

  • Indegene Limited provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies.


  • Domain expertise in healthcare.

  • Robust digital capabilities and in-house developed technology portfolio.

  • Track record of establishing long-standing client relationships.

  • Global delivery model.

  • Experienced management and motivated talent pool supported by marquee investors.


  • Its business is solely focused on the life sciences industry and may be adversely impacted by factors affecting the life sciences industry, including the growth of the overall life sciences industry, outsourcing and other trends.

  • As its business is solely focused on the life sciences industry and a significant portion of its business is attributable to certain large clients located in North America and Europe, its business and profitability is dependent on factors affecting the life sciences industry and the company continuing relationships with such key clients.

  • Its business and revenue models may be unfamiliar to prospective investors.

  • The majority of its revenues are derived from the company Subsidiaries. Any disruptions in the operations of one or more of its Subsidiaries may adversely affect its business, financial condition, results of operations.

  • The company proposes to utilize approximately 52.41% of the Net Proceeds by way of investments in its Subsidiaries by way of debt, towards identified objects of the Offer. The use of such funds will be subject to the laws of the countries in which its Subsidiaries are incorporated, and the company may have limited control over the manner in which such funds are utilized.


All values in Cr

Mar-2021 Mar-2022 Mar-2023 3-Yr trend
Revenue 966.27 (50.30%) 1,664.61 (72.30%) 2,306.13 (38.50%)
Gross Profit 966.27 (50.30%) 1,664.61 (72.30%) 2,306.13 (38.50%)
Net Income 966.27 (50.30%) 1,664.61 (72.30%) 2,306.13 (38.50%)
Assets 966.27 (50.30%) 1,664.61 (72.30%) 2,306.13 (38.50%)
Liabilities 966.27 (50.30%) 1,664.61 (72.30%) 2,306.13 (38.50%)

Book Running Managers

  • Kotak Mahindra Capital Company Ltd
  • Citigroup Global Markets India Pvt Ltd
  • J.P. Morgan India Pvt Ltd
  • Nomura Financial Advisory & Sec. (India) Pvt Ltd

Registrar & Transfer Agent

Link Intime India Pvt Ltd

C-101 247 Park,
L B S Marg,
Vikhroli West - Mumbai-400083
Phone : 91-22-49186000 Fax: 91-22-49186060

Company Contact Information

Aspen Block G4 3rd Flr Manyata,
Embassy Busi. Park Nagawara,
Bengaluru - 560045
Phone : 91-80-4674 4567/+91-80-4644 7777 Email :

Offer Related Information

Initial public offering of 40,766,550* equity shares of face value of Rs. 2 each ("Equity Shares") of Indegene Limited (The "Company" or the "Company") for cash at a price of Rs. 452 per equity share (including a premium of Rs. 450 per equity share) ("Offer Price") aggregating Rs. 1841.76 crores* (the "Offer") comprising a fresh issue of 16,833,818* equity shares aggregating to Rs. 760.00 crores (the "Fresh Issue") and an offer for sale of 23,932,732* equity shares aggregating to Rs. 1081.76... More


  • No Data Found.

Take your research to the next level.
Login now to unlock Exclusive Features!

Take your research to the next level.
Login now to unlock Exclusive Features!

Download Our App On: